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Microglia are immune cells in the central nervous system (CNS) and essential 
for homeostasis that are important for both neuroprotection and neurotoxicity, and are 
activated in a variety of CNS diseases. Microglia aggravate cognitive impairment 
induced by chronic cerebral hypoperfusion, but their precise roles under these 
conditions remain unknown. Here, we used PLX3397, a colony-stimulating factor 1 
receptor inhibitor, to deplete microglia in mice with chronic cerebral hypoperfusion 
induced by bilateral common carotid artery stenosis (BCAS). Cognitive impairment 
induced 28 days after BCAS was significantly improved in mice fed a diet containing 
PLX3397. In PLX3397-fed mice, microglia were depleted and white matter injury 
induced by BCAS was suppressed. In addition, the expression of proinflammatory 
cytokines, interleukin 6 and tumor necrosis factor alpha, was suppressed in 
PLX3397-fed mice. Taken together, these findings suggest that microglia play 
destructive roles in the development of cognitive impairment and white matter injury 
induced by chronic cerebral hypoperfusion. Thus, microglia represent a potential 
therapeutic target for chronic cerebral hypoperfusion-related diseases. 
Keywords: chronic cerebral hypoperfusion, cognitive impairment, white matter injury, 
microglia, cytokines, colony-stimulating factor 1 
Abbreviations: BCAS, bilateral common carotid artery stenosis; CNS, central nervous 
system; GSTpi, glutathione S-transferase Pi; CSF1R, colony-stimulating factor 1 
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Microglia are immune cells in the central nervous system (CNS) [1] that 
maintain CNS homeostasis [2]. These cells are important for both neuroprotection and 
neurotoxicity and are activated in a variety of CNS diseases, such as Alzheimer’s 
disease [3], frontotemporal dementia [4], and ischemic stroke [5], and aging [6]. 
Dystrophic changes to microglia occur in the aged human brain [7], and recent studies 
suggest that microglia exhibit regional diversity and sensitivities to aging, with multiple 
subtypes activated in a variety of CNS diseases [8, 9]. However, the precise protective 
and destructive roles of microglia and their contributions to disease have not been 
completely elucidated. 
Chronic cerebral hypoperfusion contributes to the progression of inflammatory 
responses [10], and chronic cerebral hypoperfusion-induced cognitive impairment is 
highly associated with inflammation in mice [11] and humans [12]. We previously 
demonstrated that the activation of microglia via transient receptor potential melastatin 
2, a Ca2+-permeable channel abundantly expressed in immune cells, aggravates this 
cognitive impairment [13]. In the present study, to clarify the role of microglia in this 
effect, we examined the pathophysiology of chronic cerebral hypoperfusion in mice 
administered a colony-stimulating factor 1 receptor (CSF1R) inhibitor that has been 
shown to deplete microglia [14]. CSF1R is an essential regulator of myeloid lineage 
cells. Dietary treatment of mice with the CSF1R inhibitor PLX3397 for 21 days 
depletes virtually all microglia and has very few effects on peripheral myeloid cells and 
neurological function [15]. Mice were fed a diet containing PLX3397 for 21 days before 
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undergoing bilateral common carotid artery stenosis (BCAS) to induce chronic cerebral 
hypoperfusion. We then performed cognitive assessments in these mice and examined 
the extent of white matter damage. 
 
Materials and Methods 
Animals and food 
All experiments were conducted in accordance with the ethical guidelines of the 
Kyoto University animal experimentation committee and with the guidelines of the 
Japanese Pharmacological Society. Male C57BL/6J mice (8–12 weeks old, 20–30 g) 
were purchased from Japan SLC. All mice were housed at a constant ambient 
temperature of 22 ± 2°C under a 12 h light/dark cycle and given ad libitum access to 
water and food. 
 To deplete microglia, mice were fed chow containing PLX3397 (290 mg/kg) for 
21 consecutive days prior to BCAS and until the end of experiments. Control mice were 
fed standard chow. 
 
BCAS 
Mice were subjected to BCAS using microcoils with an internal diameter of 0.18 
mm (Sawane Spring), as previously described [13, 16]. First, mice were anesthetized 
with 3% isoflurane in 30% O2 and 70% N2O and maintained on 1.5% isoflurane in 30% 
O2 and 70% N2O using a face mask. After a midline skin incision, the microcoil was 
applied to the bilateral common carotid arteries. Control animals were subjected to a 
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sham operation in which the bilateral common carotid arteries were isolated but the 
microcoil was not applied. 
 
Novel object recognition test 
The novel object recognition test was performed 28 days after the surgery. Mice 
were habituated to a black box (30 × 30 × 30 cm) for 3 days (10 min a day) under dim 
illumination (30 lux). In the training session, the mice were allowed to freely interact 
for 10 min with two different objects (a yellow triangular prism and a blue quadrangular 
pyramid) placed in the box. 6 h later, the blue quadrangular object was replaced with a 
novel wooden ball in the test session. The total exploratory time was defined as the time 
spent exploring both of the objects, and was considered an indicator of locomotor 
activity. Exploratory preference was defined as the ratio of the time spent exploring the 
blue quadrangular object in the training session and the wooden ball in the test session 
versus the total time spent exploring both of the objects and was considered an indicator 
of recognition memory. 
 
Myelin staining 
Mice were intraperitoneally injected with 50 mg/kg body weight pentobarbital 
or a cocktail of three different anesthetic agents (0.3 mg/kg medetomidine, 4.0 mg/kg 
midazolam, and 5.0 mg/kg butorphanol) and perfused transcardially with K+-free 
phosphate-buffered saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer. 
Brains were stored in the fixative for 3 h and then transferred to 15% sucrose in 0.1 M 
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phosphate buffer for 24 h. Coronal sections (20 µm) were cut using a cryomicrotome 
and incubated in 0.1% Triton X-100 in phosphate-buffered saline for at least 20 min. 
The sections were then incubated with Fluoromyelin green (1:1000; Invitrogen) for 20 
min at room temperature. Fluorescence was visualized with an Olympus Fluoview 
microscope equipped with a laser scanning confocal imaging system. The mean 
intensity of Fluoromyelin staining in the corpus callosum was measured in a 200 × 200 
µm field at approximately 0.7 mm anterior to bregma. 
 
Immunofluorescence 
Coronal sections were incubated overnight at 4°C with primary rabbit antibodies 
for glutathione S-transferase Pi (GSTpi) (1:200; MBL Life Science) or Iba1 (1:500; 
Wako Pure Chemical Industries). Sections were then incubated with fluorescent-labeled 
secondary antibodies (Alexa Fluor 488- or 594-labeled donkey anti-rabbit IgG, 1:300; 
Invitrogen) at room temperature for 1.5 h in the dark. Images were captured with a 
confocal fluorescence microscope. Iba1-positive cells in a 0.125 mm2 field of the corpus 
callosum 0.7 mm anterior to bregma were counted. 
 
Real-time PCR 
Samples of the corpus callosum were dissected from 2 mm-thick coronal brain 
slices and immediately frozen in liquid nitrogen for storage at −80°C until use. Total 
RNA was isolated using ISOGEN reagent (Nippon Gene) in accordance with the 
manufacturer’s suggested protocols, and cDNA was synthesized from 1 μg of total RNA 
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using ReverTra Ace (Toyobo). Real-time quantitative PCR was performed using the 
StepOne real-time PCR system (Life Technologies). The final reaction volume was 20 
µl (25 ng of cDNA plus THUNDERBIRD SYBR qPCR mix; Toyobo). The PCR 
conditions were as follows: 10 min at 95°C, followed by 40 cycles at 95°C for 10 s and 
60°C for 1 min. The following oligonucleotide primers were used: interleukin 6 (IL6), 
5′-GTG GCT AAG GAC CAA GAC CA-3′ and 5′-TAA CGC ACT AGG TTT GCC 
GA-3′; tumor necrosis factor alpha (TNFα), 5′-TGC CTA TGT CTC AGC CTC TTC-3′ 
and 5′-GAG GCC ATT TGG GAA CTT CT-3′; and 18S rRNA, 5′-GCA ATT ATT CCC 
CAT GAA CG-3′ and 5′-GGC CTC ACT AAA CCA TCC AA-3′. The amount of 18S 
rRNA in samples was used to normalize the mRNA content (the mRNA level was 
expressed relative to that of the corresponding control). 
 
Experimental design and statistical analysis 
Statistical analysis was performed using Prism 7 software (GraphPad Software). 
Briefly, for comparisons between multiple experimental groups, a two-way analysis of 
variance with Bonferroni’s post hoc test was used as appropriate. In all cases, a P value 
of < 0.05 was considered statistically significant. Data are given as means ± SEM. 
 Each data point in the figures represents one sample (section or corpus callosum 
sample) from one mouse. The numbers of animals used in each experiment are indicated 




Assessment of BCAS-induced cognitive impairment and the effect of microglial 
depletion 
Cognitive impairment was assessed with the novel object recognition test 28 
days after BCAS in mice fed PLX3397-containing chow or control diet beginning 21 
days before the surgery (Fig. 1A). There were no differences between the groups in the 
total time spent exploring the two objects during the training and test sessions (Fig. 1B, 
C), demonstrating that the BCAS operation and microglial depletion did not affect 
locomotor activity. Exploratory preferences for the two different objects were ~50%, 
and there were no differences between the groups during the training session (Fig. 1D). 
However, BCAS-operated mice displayed a significantly reduced exploratory 
preference for the novel object compared with that by the sham group fed the control 
diet, and the decrease was significantly attenuated in the PLX3397-fed group during the 
test session (Fig. 1E). These results imply that the depletion of microglia ameliorates 
cognitive impairment induced by chronic cerebral hypoperfusion. 
 
Assessment of microglial depletion and BCAS-induced white matter injury 
Histological assays were performed 28 days after BCAS to assess microglial 
depletion and white matter injury (Fig. 2A). Microglial depletion by PLX3397 was 
confirmed by immunostaining for Iba1, a marker of microglia and macrophages, in the 
corpus callosum (Fig. 2B, C). Whereas control diet-fed mice displayed a significant 
increase in the number of Iba1-positive cells 28 days after BCAS, microglial depletion 
was maintained in PLX3397-fed mice. These results show that BCAS induces activation 
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of microglia and that these cells remain depleted in animals treated with PLX3397. 
 As white matter injury is a characteristic of chronic cerebral hypoperfusion [13, 
17] and associated with cognitive impairment in vascular dementia [18], we assessed 
myelin staining in the corpus callosum after chronic cerebral hypoperfusion with and 
without microglial depletion. In BCAS-operated control diet-fed mice, there was a 
tendency to decrease in myelin density compared with that in the sham controls. By 
contrast, PLX3397-fed mice did not exhibit this decrease and had a significantly greater 
myelin density than control diet-fed mice after BCAS (Fig. 2D, E). Moreover, 
immunostaining for GSTpi revealed that BCAS significantly reduced the number of 
oligodendrocytes in control diet-fed mice but not PLX3397-fed mice (Fig. 2F, G). These 
results suggest that the depletion of microglia prevents BCAS-induced white matter 
injury. 
 
BCAS-induced changes in inflammatory responses in the corpus callosum 
To investigate inflammation in chronic cerebral hypoperfusion, the expression of 
proinflammatory cytokines in the corpus callosum was measured by real-time 
quantitative PCR 14 days after BCAS (Fig. 3A), a time at which we previously 
determined that there is an increase in proinflammatory cytokines and microglial 
markers [13]. IL6 mRNA expression was significantly increased after BCAS in control 
diet-fed mice and significantly lower in PLX3397-fed mice (Fig. 3B). Similarly, the 
expression of TNFα was significantly suppressed in PLX3397-fed mice after BCAS 
(Fig. 3C). These results suggest that the depletion of microglia reduces inflammatory 
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responses to chronic cerebral hypoperfusion. 
 
Discussion 
In the present study, we showed that the depletion of microglia by PLX3397 
suppressed inflammation, white matter injury, and cognitive impairment induced by 
BCAS, suggesting that the activation of microglia contributes to a variety of 
pathological changes induced by chronic cerebral hypoperfusion. 
 In our previous study, we found that the inhibition of microglial activation by 
minocycline, a tetracycline antibiotic, ameliorated the white matter injury and cognitive 
impairment induced by BCAS [13]. Therefore, we concluded that microglia play 
important roles in chronic cerebral hypoperfusion-related changes. However, 
minocycline also inhibits the activation of macrophages [19] and astrocytes [20, 21] as 
well as 5-lipoxygenase [22]. To confirm that the benefits were a result of microglial 
effects, here we treated the mice with the CSF1R inhibitor PLX3397, which along with 
PLX5622 has been used in a wide variety of CNS disease studies. For example, CSF1R 
inhibitors decrease lesion size, brain edema, and neurological deficits in a mouse 
intracerebral hemorrhage model [23], and CSF1R inhibitor-induced depletion of 
microglia suppresses neuritic plaque accumulation and improves cognitive impairment 
in a mouse model of Alzheimer’s disease [24]. In this context, the study using aging 
mice showed that repopulation of microglia after elimination by the CSF1R inhibitor 
restores microglial morphology (repopulated cells resemble young cells) and 
ameliorates age-related cognitive dysfunction [25]. Other studies indicate that the 
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depletion of microglia also improves neurological deficits in mouse models of 
demyelination-related diseases, such as catatonia [26] and multiple sclerosis [27, 28]. 
However, Jin et al. found that brain infarctions and neurological deficits were 
exacerbated by the depletion of microglia in mice with middle cerebral artery occlusion, 
a model of focal cerebral ischemia [29], suggesting that microglia restricted the 
ischemia-induced astrocyte response and conferred neuroprotective function. Moreover, 
physical exercise has also been shown to alleviate cognitive impairment and 
demyelination in a two-vessel occlusion model of chronic cerebral hypoperfusion in rats, 
in which the benefit was associated with a polarization from M1 toward M2 microglia 
[30]. Because treatment with PLX3397 in the present study eliminated virtually all 
microglia, including M1 and M2 subtypes, further investigations are required to clarify 
the difference of microglial subtypes in chronic cerebral hypoperfusion-related diseases. 
 IL6 and TNFα are cytokines that are secreted by astrocytes as well as microglia 
[31]. The expression of these cytokines was reduced by PLX3397 in BCAS-operated 
mice as well as in sham-operated mice, suggesting that microglia are primarily 
responsible for the expression of IL6 and TNFα in the corpus callosum. However, the 
reduced expression in animals treated with PLX3397 may have resulted in reduced 
signaling in astrocytes, as they express the receptors for IL6 and TNFα among others 
[32]. Therefore, further investigations into the involvement of astrocytes in chronic 
cerebral hypoperfusion are needed. Nevertheless, the findings implicate the secretion of 
proinflammatory cytokines from microglia in the cognitive impairment and white 
matter injury induced by BCAS. 
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 In conclusion, the results of this study indicate that microglia play destructive 
roles in chronic cerebral hypoperfusion-related diseases. The timing of microglial 
activation in relation to the associated white matter injury and cognitive impairment is 
unclear, as the depletion was initiated 21 days before BCAS in the present study. 
Studies with PLX5622, a CSF1R inhibitor that eliminates microglia with just 7 days of 
treatment, may help to clarify this and to determine the time point at which microglial 
depletion would be most therapeutic for chronic cerebral hypoperfusion. Additional 
studies may also elucidate whether and/or how microglial repopulation affects chronic 
cerebral hypoperfusion-induced outcomes. Nevertheless, the findings presented here 
indicate that microglia represent a potential therapeutic target for clinical interventions 
to treat chronic cerebral hypoperfusion-related diseases.  
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Figure 1. BCAS-induced cognitive impairment was not observed in PLX3397-fed 
mice. 
(A) The experimental time course for the novel object recognition test (NORT). Total
times spent exploring the two objects during training (B) and test (C) sessions. 
Exploratory preferences for the two different objects during the training (D) and test (E) 
sessions. Values are means ± SEM. **P < 0.01 (n = 12–17). 
Figure 2. BCAS-induced increases in Iba1-positive cells and white matter injury 
were not observed in PLX3397-fed mice. 
(A) The experimental time course for histological assays. Representative images (B)
and quantification (C) of Iba1 immunostaining in the corpus callosum (n = 9–14). 
Representative images of myelin staining (D) and quantification of relative myelin 
density (E) in the corpus callosum (n = 9–14). Representative images (F) and 
quantification (G) of GSTpi immunostaining in the corpus callosum (n = 6–11). Scale 
bars, 100 µm. Values are means ± SEM. *P < 0.05, ***P < 0.001. 
Figure 3. Proinflammatory cytokine expression in the corpus callosum was 
suppressed in PLX3397-fed mice. 
(A) The experimental time course for real-time quantitative PCR. Expression of IL6 (B)
and TNFα (C) mRNA in the corpus callosum (n = 3–4). Values are means ± SEM. *P < 
0.05, **P < 0.01. 
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